Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Eisai has entered into a collaborative research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs) toward drug discovery in oncology.

Eisai collaborates with University of Dundee on cancer drug discovery

ROTACs consist of two covalently linked protein-binding molecules: one capable of engaging an ubiquitin ligase (E3 ligase) and another that binds to a target protein meant for degradation. PROTACs work by recruiting an E3 ligase to tag the target protein for ubiquitination for degradation through the intracellular degradation system. It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

In this collaboration research, Professor Alessio Ciulli, one of the global pioneers in the field of PROTACs research, at the School of Life Sciences, University of Dundee is responsible for directing the research. The collaboration combines the world-leading expertise and technology of the Professor Alessio Ciulli laboratory in PROTACs research with Eisai’s discovery researches and clinical development experiences in oncology area as well as findings of target protein degradation based on our basic researches to aim to create innovative new drugs.

Under this agreement, Eisai has the option rights to develop and commercialize the compounds resulted from this collaboration research. If Eisai exercises the options, an upfront, milestone payments, and royalties on sales will be paid.

Read More

Related news

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

FDA Approves rfxcel for Verification Router Service (VRS) Pilot

15 Aug 2019

rfxcel, the global leader in supply chain compliance and serialization solutions, has been approved by the U.S. Food and Drug Administration (FDA) to conduct a pilot to extend the testing of the Verification Router Service (VRS) for saleable returns.

Read more 
rfxcel Awarded ISO 9001:2015 Certification

rfxcel Awarded ISO 9001:2015 Certification

14 Aug 2019

rfxcel, the leader in track and trace solutions for global supply chains announced that it is now ISO 9001:2015 certified for Quality Management Systems.

Read more 
How real-world data can revolutionise drug development

How real-world data can revolutionise drug development

9 Aug 2019

Utilising the current data environment and its data pools for the benefit of advancing research.

Read more 
Using mobile phones to fight Alzheimer’s disease

Using mobile phones to fight Alzheimer’s disease

8 Aug 2019

Researchers study how radiofrequency electromagnetic fields could be used in Alzheimer’s disease therapy.

Read more 
Automation-compatible prepared culture media plate technology

Automation-compatible prepared culture media plate technology

6 Aug 2019

Thermo Fisher Scientific's SmartPlate format brings together Oxoid and Remel prepared culture media with a durable, universal plate design, helping customers to deliver accurate results across both automated and manual methods.

Read more 
Researchers develop 3D printed ingestible pill

Researchers develop 3D printed ingestible pill

4 Aug 2019

Represents the first non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract.

Read more 
Needle free: Erase wrinkles without injection

Needle free: Erase wrinkles without injection

15 Jul 2019

Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more